



4th May 2013

Aurobindo Pharma receives USFDA Approvals for Tamsulosin HCL Capsules and Clindamycin Palmitate Hydrochloride for Oral Solution (Pediatric)

Aurobindo Pharma Limited is pleased to announce that the company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Tamsulosin Hydrochloride Capsules USP 0.4mg (ANDA 202433) and Clindamycin Palmitate Hydrochloride for Oral Solution USP(Pediatric), 75mg (base)/5mL (ANDA 202409). The products will be launched soon.

Tamsulosin Hydrochloride Capsules USP 0.4mg is the generic equivalent of Boehringer Ingelheim Pharmaceuticals' Flomax® Capsules, 0.4mg and is indicated for the treatment of symptoms of an enlarged prostate (Benign Prostatic Hyperplasia - BPH) in men. The market size of the product is estimated to be US\$244 Million for the twelve months ending September 2012 according to IMS.

Clindamycin Palmitate Hydrochloride for Oral Solution USP(Pediatric), 75mg (base)/5mL is the generic equivalent of Pharmacia & Upjohn's Cleocin® Pediatric For Oral Solution, 75mg (base)/5mL and is indicated for indicated in the treatment of serious infections caused by susceptible anaerobic bacteria in infants. The market size of the product is estimated to be US\$57 Million for the twelve months ending September 2012 according to IMS.

Aurobindo now has a total of 190 ANDA approvals (163 Final approvals including 4 from Aurolife Pharma LLC and 27 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com